Related Experiment Video
Updated: Nov 29, 2025

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
Published on: April 21, 2012
Cutaneous Leishmaniasis Treated with Miltefosine: A Case Series of 10 Paediatric Patients
Ayelet Ollech1, Michal Solomon, Amir Horev
1Department of Dermatology, Rabin Medical Center, Beilinson Hospital Petach Tikva, Petach Tikva 49100, Israel.
Insights
Miltefosine shows promise as an effective and safe oral treatment for pediatric Old World cutaneous leishmaniasis. This study found an 80% complete response rate in children with Leishmania tropica or Leishmania major infections.
Area of Science:
- Dermatology
- Infectious Diseases
- Tropical Medicine
Background:
- Cutaneous leishmaniasis presents significant treatment challenges in children.
- Old World cutaneous leishmaniasis requires effective and safe therapeutic options for pediatric patients.
Purpose of the Study:
- To evaluate the efficacy and safety of miltefosine for treating Old World cutaneous leishmaniasis in children.
- To assess treatment outcomes in pediatric patients with Leishmania tropica and Leishmania major infections.
Main Methods:
- A multicenter retrospective review was conducted on 10 pediatric patients (≤18 years) treated with miltefosine in Israel.
- Data collected included patient age, Leishmania species, treatment duration, follow-up period, treatment response, and adverse effects.
Main Results:
- Complete response to miltefosine was observed in 80% (8/10) of pediatric patients.
- Treatment failure occurred in 20% (2/10) of cases.
- Adverse effects associated with miltefosine treatment were minimal.
Conclusions:
- Oral miltefosine appears to be an effective and safe treatment option for pediatric Old World cutaneous leishmaniasis caused by Leishmania tropica or Leishmania major.
- Further research is necessary to definitively establish miltefosine's role in treating pediatric cutaneous leishmaniasis.
Abstract:
Cutaneous leishmaniasis poses a therapeutic challenge in the paediatric population. The aim of this study was to assess the efficacy and safety of miltefosine treatment for Old World cutaneous leishmaniasis in paediatric patients. A multicentre retrospective review of 10 children (≤ 18 years of age) with cutaneous leishmaniasis treated with miltefosine in Israel was performed. Mean ± standard deviation age at diagnosis was 9.1 ± 5.0 years. The Leishmania species diagnosed was L. tropica in 8 cases and Leishmania major in 2 cases. Mean ± standard deviation duration of treatment was 44.8 ± 20.6 days, with a mean follow-up period of 12.1 ± 17.1 months. Complete response was noted in 8 (80%) patients. Treatment failure was noted in 2 (20%) cases. Side-effects related to the medication were minimal. In conclusion, oral miltefosine may be an effective and safe treatment for Old World cutaneous leishmaniasis caused by Leishmania tropica or Leishmania major in children. However, further studies are warranted to draw a definite conclusion.
More Related Videos
12:22A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line
Published on: December 30, 2012
05:55In Vivo Imaging of Leishmania infantum-infected Hamsters by Gingival Inoculation of Axenic Amastigotes Expressing Luciferase
Published on: April 4, 2025
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Fungal Phylum Microsporidia